Abstract:Abstract Background Venous thromboembolism (VTE) is a leading cause of mortality in patients with cancer and is associated with significant morbidity and healthcare expenditure. The risk of VTE is also increased following the insertion of a central venous catheter (CVC) for chemotherapy deliverance and supportive care. The risks and benefits of primary thromboprophylaxis in patients with cancer and newly inserted CVC are unclear. Objective We sought to assess the rates of VTE and major bleeding complications to determine the safety and efficacy of primary thromboprophylaxis in adult patients with cancer and a CVC. Methods A systematic search of MEDLINE, EMBASE, and all EBM was conducted. Randomized controlled trials (RCTs) of adult patients with cancer and a CVC receiving primary thromboprophylaxis or observation/placebo were included. The primary efficacy and safety outcomes were total VTE and major bleeding episodes, respectively. Results A total of 9 RCTs (3155 patients) were included in the analysis. The total rates of VTE were significantly lower in patients receiving primary thromboprophylaxis compared to those not receiving primary prevention (7.6% vs. 13%; Odds Ratio (OR) 0.51, 95% CI 0.32 to 0.82, p < 0.01, I2 = 52%) (Figure 1). The rate of major bleeding complication was not increased in patients receiving thromboprophylaxis (0.9% vs. 0.7%; OR 1.12, 95% CI 0.29 to 4.40, p = 0.87, I2 = 32%) (Figure 2). Conclusions Primary thromboprophylaxis significantly reduced the risk of VTE without increasing the risk of major bleeding complications in patients with cancer and CVC. Future studies are needed to confirm these findings. Figure 1 Figure 1. Disclosures Wang: Servier: Membership on an entity's Board of Directors or advisory committees; Leo Pharma: Research Funding. Ikesaka: LEO Pharma: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees. Wells: Bristol-Myers Squibb: Honoraria; Pfizer: Honoraria; Bayer: Honoraria; BMS/Pfizer: Research Funding; Servier: Honoraria. Carrier: Servier: Honoraria; Boehringer Ingelheim: Honoraria; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Aspen: Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Honoraria; Bayer: Honoraria, Membership on an entity's Board of Directors or advisory committees; LEO Pharma: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi Aventis: Honoraria, Membership on an entity's Board of Directors or advisory committees.

Prevention of venous thromboembolism in patients with advanced lung cancer receiving chemotherapy: a combined analysis of the PROTECHT and TOPIC‐2 studies

Incidence of Venous Thromboembolism and Hemorrhage in Chinese Patients after Pulmonary Lobectomy: Mechanical Prophylaxis or Mechanical Prophylaxis Combined with Pharmacological Prophylaxis: a Randomized Controlled Trial.

[Prophylaxis of thrombosis induced by chemotherapy or central venous catheters]

The efficacy of low molecular weight heparin in sixty cancer patients with venous thromboembolism

Transjugular Intrahepatic Portosystemic Shunt Versus Endoscopic Therapy in the Secondary Prophylaxis of Variceal Rebleeding in Cirrhotic Patients: Meta-Analysis Update.

Efficacy and Safety of Adjunctive Anticoagulation in Patients with Lung Cancer Without Indication for Anticoagulants: a Systematic Review and Meta-Analysis

Efficacy and safety of primary thromboprophylaxis for the prevention of venous thromboembolism in patients with cancer and a central venous catheter: A systematic review and meta-analysis

Efficacy and Safety of Primary Thromboprophylaxis for the Prevention of Venous Thromboembolism in Patients with Cancer and Central Venous Catheter: A Systematic Review and Meta-Analysis

Preventative and curative treatment of venous thromboembolic disease in cancer patients

Tumor-expressed factor VII is associated with survival and regulates tumor progression in breast cancer

Limited Effect of Prevention Strategies on Incidence of Clinically Detectable Venous Thromboembolism After Lung Transplantation

The impact of venorelbine plus cisplatin chemotherapy on coagulation markers in non -small cell lung cancer patients

Hypercoagulability State Combined with Post-Treatment Hypofibrinolysis in Invasive Breast Cancer: A Seven-Year Follow-Up Evaluating Disease-Free and Overall Survival

Effect of Low Molecular Weight Heparin on Venous Thromboembolism Disease in Thoracotomy Patients with Cancer.

Intensify Standardized Anticoagulation for Cancer-Associated Pulmonary Embolism: From Single-Center Real-World Data

Recombinant Factor VIIa for Variceal Bleeding in Patients with Advanced Cirrhosis: A Randomized, Controlled Trial

Recent advances in the treatment and prevention of venous thromboembolism in cancer patients: role of the direct oral anticoagulants and their unique challenges

Microvesicle Tissue Factor Procoagulant Activity Is Elevated and Correlated With Disease Severity in Patients With Cirrhosis

TGFβ1 plasma levels and clot lysis assay to better characterize patients after a first unprovoked episode of pulmonary embolism

Clinical Evaluation Of Plasma Coagulation Parameters In Patients With Advanced-Stage Non-Small Cell Lung Cancer Treated With Palliative Chemotherapy In China

Prognostic significance of tissue factor in patients with pancreatic cancer: a systematic review protocol